- Home
- PPBT vs APDN Comparison
PPBT vs APDN Comparison
Compare PPBT & APDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PPBT
- APDN
- Stock Information
- Founded
- PPBT 2010
- APDN 1983
- Country
- PPBT Israel
- APDN United States
- Employees
- PPBT N/A
- APDN N/A
- Industry
- PPBT Biotechnology: Pharmaceutical Preparations
- APDN Other Consumer Services
- Sector
- PPBT Health Care
- APDN Consumer Discretionary
- Exchange
- PPBT Nasdaq
- APDN Nasdaq
- Market Cap
- PPBT 2.1M
- APDN 1.7M
- IPO Year
- PPBT N/A
- APDN N/A
- Fundamental
- Price
- PPBT $0.61
- APDN $2.90
- Analyst Decision
- PPBT Strong Buy
- APDN
- Analyst Count
- PPBT 1
- APDN 0
- Target Price
- PPBT $33.00
- APDN N/A
- AVG Volume (30 Days)
- PPBT 2.9M
- APDN 252.9K
- Earning Date
- PPBT 11-14-2025
- APDN 08-26-2025
- Dividend Yield
- PPBT N/A
- APDN N/A
- EPS Growth
- PPBT N/A
- APDN N/A
- EPS
- PPBT N/A
- APDN 211.51
- Revenue
- PPBT N/A
- APDN $3,743,063.00
- Revenue This Year
- PPBT N/A
- APDN $57.08
- Revenue Next Year
- PPBT N/A
- APDN $40.00
- P/E Ratio
- PPBT N/A
- APDN $0.01
- Revenue Growth
- PPBT N/A
- APDN 55.60
- 52 Week Low
- PPBT $0.53
- APDN $2.13
- 52 Week High
- PPBT $13.95
- APDN $1,072.50
- Technical
- Relative Strength Index (RSI)
- PPBT 14.86
- APDN 40.67
- Support Level
- PPBT $0.53
- APDN $2.40
- Resistance Level
- PPBT $2.36
- APDN $2.97
- Average True Range (ATR)
- PPBT 0.14
- APDN 0.31
- MACD
- PPBT -0.05
- APDN 0.08
- Stochastic Oscillator
- PPBT 3.95
- APDN 45.29
About PPBT Purple Biotech Ltd.
Purple Biotech Ltd is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, and to create treatments for people with cancer. Its oncology pipeline includes NT219: A dual inhibitor, small molecule that simultaneously targets Insulin Receptor Substrate 1 and 2 (IRS1/2) and Signal Transducer and Activator of Transcription (STAT3), two survival signal transduction pathways driving the development of cancer drug resistance. and CM24: is a humanized monoclonal antibody designed to block the interactions of Carcinoembryonic Antigen Related Cell Adhesion Molecule 1 (CEACAM1), a glycoprotein that plays a key role in immune regulation, cell adhesion, and tumor progression, CAPTN3.
About APDN Applied DNA Sciences Inc.
Applied DNA Sciences Inc is a biotechnology company developing and commercializing technologies to produce and detect deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). The company operates in three business segments- Therapeutic DNA Production Services, MDx Testing Services, and DNA Tagging and Security Products and Services. It generates majority of its revenue from the MDx Testing Services which is involved in performing and developing clinical molecular diagnostic and genetic tests and clinical laboratory testing services. The company provides its products and services under the brand of Applied DNA Sciences, SigNature molecular tags, SigNature T molecular tags, fiberTyping, SigNify and others.